Oculis Enrolls First Patient in PREDICT-1, Advancing Precision DED Therapy – But Platform Risk Remains

What happened

Oculis announced the first patient randomized in the PREDICT-1 registrational trial of Licaminlimab (OCS-02) for dry eye disease, a genotype-guided therapy targeting TNFR1-positive patients. This marks a routine milestone in a program that already had FDA alignment and expected Q4 2025 initiation, so it does not materially de-risk the broader platform. Meanwhile, the true value inflection remains the DIAMOND DME topline in 2Q26, on which the entire equity is staked given a ~$1.2B market cap and heavy dilution from three concurrent registrational trials. The master report's probability-weighted implied value of ~$24 is close to the current ~$23, offering limited upside with significant downside if DIAMOND disappoints. Thus, while today's news is incrementally positive for the DED asset, it does not change the asymmetric risk-reward favoring patience or a lower entry point.

Implication

Today's PREDICT-1 milestone is operationally positive but expected, and does not shift the core risk-reward calculus. With a 35% bear case valuing the stock at $12, the current $23 price still reflects elevated expectations for OCS-01's DME program without data to support them. The next potential upside catalyst is DIAMOND topline in 2Q26, but even that is a binary event that could just as easily destroy value as create it. The three concurrent programs drain cash rapidly, and while the company guides to runway into 2029, any delays or expansion of trials could force further dilutive financing. For now, the risk-reward is unfavorable; wait for either a pullback into the mid-teens or positive DIAMOND data before committing capital.

Thesis delta

The news of PREDICT-1 enrollment does not alter our bearish thesis; it was already part of the base case. We see no shift in the expected value framework: the stock remains a potential sell at $23, and we continue to recommend waiting for a lower entry near $15 or de-risking via DIAMOND data before adding exposure.